KIORA PHARMACEUTICALS INC (KPRX)

Company Profile

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Encinitas, California and currently employs 12 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing and commercializing therapies for the treatment of ophthalmic diseases. Its pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+). KIO-101 is a next-generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase. KIO-201 is a synthetic modified hyaluronic acid (HA) capable of coating the ocular surface and designed to resist degradation under conditions present in the eye.

Company Info

KIORA PHARMACEUTICALS INC

332 Encinitas Boulevard, Suite 102

Encinitas CALIFORNIA

P: 17817888869

CEO: Franz Obermayr

Employees: 12

Website: https://kiorapharma.com/